SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lyka Labs - Quaterly Results

20 May 2022 Evaluate
A decent increase of about 55.34% in the turnover to Rs. 276.83 millions was observed for the quarter ended March 2022. The turnover stood at Rs. 178.21 millions during the similar quarter previous year.The Net Loss for the quarter ended March 2022 is Rs. -152.35 millions as compared to Net Profit of Rs. 2.33 millions of corresponding quarter ended March 2021OP of the company witnessed a marginal growth to 122.22 millions from 63.07 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 276.83 178.21 55.34 1643.49 622.63 163.96 1643.49 622.63 163.96
Other Income 6.60 8.48 -22.17 27.20 22.10 23.08 27.20 22.10 23.08
PBIDT 122.22 63.07 93.78 1002.19 166.35 502.46 1002.19 166.35 502.46
Interest 29.10 63.05 -53.85 199.21 255.53 -22.04 199.21 255.53 -22.04
PBDT 65.09 -16.94 -484.24 756.30 -103.47 -830.94 756.30 -103.47 -830.94
Depreciation 91.31 19.50 368.26 153.89 80.50 91.17 153.89 80.50 91.17
PBT -26.22 -36.44 -28.05 602.41 -183.97 -427.45 602.41 -183.97 -427.45
TAX 126.13 -38.77 -425.33 203.38 -39.36 -616.72 203.38 -39.36 -616.72
Deferred Tax 126.13 -38.77 -425.33 203.38 -39.36 -616.72 203.38 -39.36 -616.72
PAT -152.35 2.33 -6638.63 399.03 -144.61 -375.94 399.03 -144.61 -375.94
Equity 286.90 286.90 0.00 286.90 286.90 0.00 286.90 286.90 0.00
PBIDTM(%) 44.15 35.39 24.75 60.98 26.72 128.24 60.98 26.72 128.24

Lyka Labs Share Price

59.80 -0.68 (-1.12%)
24-Apr-2026 11:44 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1621.20
Dr. Reddys Lab 1317.95
Cipla 1279.85
Zydus Lifesciences 929.15
Lupin 2271.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×